Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension-Reference-Cited by-同舟云学术

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Published:2021-11-12 Issue:1 Volume:74 Page:70-80
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Deodhar Atul¹^ORCID,Heijde Désirée²,Sieper Joachim³,Van den Bosch Filip⁴,Maksymowych Walter P.⁵^ORCID,Kim Tae‐Hwan⁶^ORCID,Kishimoto Mitsumasa⁷^ORCID,Ostor Andrew⁸,Combe Bernard⁹,Sui Yunxia¹⁰,Chu Alvina D.¹⁰,Song In‐Ho¹⁰

Affiliation:

1. Oregon Health & Science University Portland

2. Leiden University Medical Center Leiden The Netherlands

3. Charité Universitätsmedizin Berlin Berlin Germany

4. VIB‐UGent Center for Inflammation Research and Ghent University Ghent Belgium

5. University of Alberta Edmonton Alberta Canada

6. Hanyang University Hospital for Rheumatic Diseases Seoul Republic of Korea

7. Kyorin University School of Medicine Tokyo Japan

8. Cabrini Medical Center and Monash University Melbourne Victoria Australia

9. Centre Hospitalier Universitaire de Montpellier and Université de Montpellier Montpellier France

10. AbbVie North Chicago Illinois United States

Funder